Form 4: Axsome Therapeutics Director, Mark E. Saad, Acquires Stock Options
SEC Form 4
Director Mark E. Saad acquired stock options for 5,799 shares of Axsome Therapeutics, Inc. on June 7, 2024.
Summary
- On June 7, 2024, Mark E. Saad, a director of Axsome Therapeutics, Inc., acquired stock options for 5,799 shares.
- The exercise price of these options is $73.90.
- The options vest in full on June 7, 2025, one year after the grant date, and expire on June 7, 2034.
- Following this transaction, Mr. Saad directly owns 5,799 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which doesn't inherently indicate positive or negative sentiment.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it may signal confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of stock option grant and transaction. |
| 06/07/2025 | Date the options vest in full. |
| 06/07/2034 | Expiration date of the options. |
| 06/11/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.